Market Newsdesk

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC; OTCQX: ALLXF) announced today that it produced a total of 2,520 ounces of gold in December 2020 bringing the total for the fourth quarter of 2020 to 7,181 ounces, up from 7,057 ounces produced in the fourth quarter last year. For the full year, the Company produced a total of 23,832 ounces of gold in 2020 which is within its annual guidance range of between 23,000 and 26,000 ounces. The Company produced a total 25,750 ounces of gold last year and over the last 10 years has produced an average of approximately 23,800 ounces per year.

Lombardo Paredes, President of Caldas Gold, commenting on the Company’s latest results, said, “We continued to gain momentum in the fourth quarter of 2020 with the implementation of the optimized mine plan in the existing upper mining operation and commencement of the plant expansion that will increase capacity from 1,200 tonnes per day (“tpd”) to 1,500 tpd by the third quarter this year. While 2020 had its challenges, having to adapt our operations to cope with COVID-19, we successfully kept our operations going throughout the year. We have also commenced preparatory activities related to the expansion of our underground mining operations into the Marmato Deep Zone (“MDZ”) while we await completion of the Marmato mining title extension, expected later this month as recently announced. Our ongoing drilling campaign in the MDZ continues to demonstrate Marmato’s prowess as a rare world-class system, both in terms of its size and grades, and we expect to have further results available shortly from our fourth quarter program. At the end of December, we had an unrestricted cash position of approximately US$32 million and a total of approximately US$240 million of funds being held in escrow from the gold notes offering and the Aris Gold private placement together with the Wheaton stream financing, all of which will become available to us to fund the MDZ Project following the mining title extension. The gold notes commenced trading on the NEO Exchange (CGC.NT.U) in November and, as of the end of December, we have another approximately US$10 million of cash being held by the trustee to fund the monthly interest payments on the gold notes over the next 20 months. With the foundation established in our first year since forming Caldas Gold, we are working closely with the management team from Aris Gold to prepare for a smooth transition and the next phase of the expansion of the Marmato Project.”

In December, the plant processed an average of 1,075 tpd at an average head grade of 2.7 g/t resulting in gold production of 2,520 ounces. This brought Marmato’s daily processing rate to an average of 909 tpd in the fourth quarter of 2020 compared with 1,009 tpd in the fourth quarter last year. Head grades improved to an average of 3.0 g/t in the fourth quarter of 2020, up from 2.7 g/t the fourth quarter last year. For the full year, the Marmato operations processed an average of 843 tpd at an average head grade of 2.7 g/t in 2020 compared with 1,015 tpd at an average head grade of 2.5 g/t last year. The Company also produced a total of 34,091 ounces of silver in 2020 compared with 39,559 ounces of silver last year.

Caldas Gold expects to release its 2020 fourth quarter and annual financial results on or about March 30, 2021. Webcast details are expected to be announced in early March.

About Caldas Gold Corp.

Caldas Gold is a Canadian junior mining company currently advancing a major expansion and modernization of its underground mining operations at its Marmato Project in the Department of Caldas, Colombia. Caldas Gold also owns 100% of the Juby Project, an advanced exploration-stage gold project located within the Shining Tree area in the southern part of the Abitibi greenstone belt about 100 km south-southeast of the Timmins gold camp. On November 23, 2020, Caldas Gold announced it had entered into a transaction with a group of investors, principally referred by Aris Gold Corporation, that resulted in a C$85 million private placement completed on December 3, 2020 and will result in changes to the management and the board of directors of the Company as well as a change in the Company’s name to “Aris Gold Corporation”. The net proceeds of the Aris Gold private placement, the management and board changes and the Company name change will all occur once certain escrow release conditions are met, including completion of the Marmato mining title extension.

Additional information on Caldas Gold can be found on its website at www.caldasgold.ca and by reviewing its profile on SEDAR at www.sedar.com.

Cautionary Statement on Forward-Looking Information:

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation concerning the business, operations and financial performance of Caldas Gold. Forward-looking statements in this press release, which are all statements other than statements of historical fact, include, but are not limited to production, the Marmato mining title extension and the timing thereof, escrow release conditions for the gold notes and the Aris Gold transaction, funding from the Wheaton stream financing and anticipated business plans or strategies. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Caldas Gold to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include the other risk factors as described under the caption “Risk Factors” in the Company’s annual information form for the financial year ended December 31, 2019 dated as of August 17, 2020 which is available for view on SEDAR at


www.sedar.com


. Forward-looking statements contained herein are made as of the date of this press release and Caldas Gold disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

For Further Information, Contact:

Mike Davies
Chief Financial Officer
(416) 360-4653
[email protected]

• Fourth-quarter 2020 ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales estimated to be approximately $26.3 million
• Full-year 2020 net sales estimated to be approximately $85.5 million
• Company names Adam Muzikant, Ph.D., Chief Business Officer
  

BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020.

“We are very pleased to report preliminary full-year 2020 ZILRETTA net sales of approximately $85.5 million,” said Michael Clayman, M.D., President and Chief Executive Officer. “Our strong sales reflect the expanding role ZILRETTA is taking in the osteoarthritis knee pain treatment paradigm. We are encouraged by our commercial performance despite the impacts of the pandemic, and our confidence in ZILRETTA’s long-term prospects continues to grow.”

Dr. Clayman added, “While ensuring the successful commercialization of ZILRETTA is our highest priority, we remain committed to building a pipeline of transformative medicines to fuel our future growth, and we are pleased to announce that Adam Muzikant, Ph.D. has been promoted to Chief Business Officer. Adam was instrumental in the transactions that led to the FX201 and FX301 programs and has been a driving force in the development of our pipeline. His extensive experience and vision make him the ideal person to assume this critical new role, and I look forward to his continued contributions in the years ahead.”

Preliminary Unaudited 2020 Results

• Net sales for the fourth quarter of 2020 are estimated to be $26.3 million.
• Net sales for the full year 2020 are estimated to be $85.5 million.
• As of December 31, 2020, the company had approximately $175 million in cash, cash equivalents, and marketable securities.

ZILRETTA Commercial Metrics

Since the launch of ZILRETTA in November 2017 through December 31, 2020:

• 4,248 accounts had purchased ZILRETTA, reflecting growth of 176 new purchasing accounts vs September 30, 2020, when 4,072 accounts had purchased product.
• 78% of purchasing accounts (3,321) placed at least one reorder, up from 3,153 accounts that had reordered ZILRETTA as of September 30, 2020.
• 1,242 accounts had made ZILRETTA purchases of more than 50 units; 1,170 accounts had purchased 11 to 50 units; and 1,836 accounts had purchased between 1 and 10 units.
• Accounts that had purchased more than 50 ZILRETTA units accounted for 307,988 of the total 345,697 ZILRETTA units purchased.

As a result of specialty distributor purchases in response to growing customer demand and a modest distributor buy-in at a small discount, the ZILRETTA inventory held by specialty distributors at year-end was slightly above the 1 to 3 weeks the company targets.

This financial information is preliminary and subject to adjustment. Flexion expects to report its complete 2020 financial results on its fourth-quarter and full-year earnings call, which will be held later in the first quarter of 2021.

Indication and Select Important Safety Information for ZILRETTA

Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.

Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.

Warnings and Precautions:

• Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration.
• Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use.
• Hypersensitivity reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.
• Joint infection and damage: A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment.

Adverse Reactions: The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.

Please see

ZilrettaLabel.com

for full Prescribing Information.

About ZILRETTA

On October 6, 2017, ZILRETTA was approved by the U.S. FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide—a commonly administered, short-acting corticosteroid—with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. Learn more at www.zilretta.com.

About Osteoarthritis (OA) of the Knee

OA, also known as degenerative joint disease, affects more than 30 million Americans and accounts for more than $185 billion in annual expenditures. In 2016, more than 15 million Americans were diagnosed with OA of the knee, and the average age of physician-diagnosed knee OA has fallen by 16 years, from 72 in the 1990s to 56 in the 2010s. The prevalence of OA is expected to continue to increase as a result of aging, obesity, and sports injuries. Each year, more than 15 million Americans are treated for OA-related knee pain, and approximately five million OA patients receive either an immediate-release corticosteroid or hyaluronic acid intra-articular injection to manage their knee pain.

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity, tenacity, transparency, and fun. Please visit www.flexiontherapeutics.com.

Forward-Looking Statements

This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future of Flexion; the long-term potential of ZILRETTA; Flexion’s business strategy and expectations with respect to its pipeline; estimated financial and operating results; expected increases in the rate of individuals with OA of the knee; and the potential therapeutic and other benefits of ZILRETTA, are forward looking statements. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the fact that the impacts and expected duration of the COVID-19 pandemic are uncertain and rapidly changing; the risk that we may not be able to successfully maintain an effective sales force to commercialize ZILRETTA; competition from alternative therapies; the risk that we may not be able to maintain and enforce our intellectual property, including intellectual property related to ZILRETTA; the risk that ZILRETTA may not be successfully commercialized or adopted; risks regarding our ability to obtain adequate reimbursement from payers for ZILRETTA; risks related to the manufacture and distribution of ZILRETTA, including our reliance on sole sources of supply and distribution; risks related to clinical trials, including potential delays, safety issues, or negative results; risks related to key employees, markets, economic conditions, health care reform, prices, and reimbursement rates; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 4, 2020, and subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Contact:

Scott Young
Vice President, Corporate Communications & Investor Relations
T: 781-305-7194
[email protected]

Julie Downs
Associate Director, Corporate Communications & Investor Relations
T: 781-305-7137
[email protected]

GUANGZHOU, China, Jan. 13, 2021 (GLOBE NEWSWIRE) — LIZHI INC. (“LIZHI” or “the Company”) (NASDAQ: LIZI), a leading online UGC audio community and interactive audio entertainment platform in China, today announced it has launched LIZHI PODCAST mini-program on WeChat to engage broader user base with high-quality podcast contents and will launch a series of new exclusive podcast on LIZHI PODCAST in the near future.

Shortly after the launch of LIZHI PODCAST, a series of new exclusive podcasts are also expected to be launched on different terminals of LIZHI PODCAST including mobile app, WeChat mini-program, and LIZHI’s automobile-based audio product across broader curated content categories including science, psychology, aesthetics, sports, which we believe will meet the demands of a broader user base.

Mr. Jinnan (Marco) Lai, Founder and Chief Executive Officer of LIZHI, commented, “We’re pleased to see the WeChat mini-program of LIZHI PODCAST has been launched, which is designed to enable users to share podcast content at their fingertips in the WeChat community and appeal to a broad user base. All the terminals on which LIZHI PODCAST operates will be fully compatible with users’ LIZHI accounts which may help us continue enriching user experiences by leveraging our AI capabilities. In addition, new exclusive podcasts to be launched will also be available on LIZHI’s automobile-based audio product, which we believe can further optimize the user experiences including the in-car audio experiences and provide more personalized content recommendation to our users. Leveraging our strong audio technologies and operating experiences, LIZHI PODCAST aims to offer a new platform for podcasts to reach a broader audience and promote engaged fan base, while enriching the audio experiences across an even wider variety of life scenarios.”

About LIZHI INC.

LIZHI INC. is a leading online UGC audio community and interactive audio entertainment platform in China, with a mission to enable everyone to showcase vocal talent. The Company is aiming to bring people closer together through voices.

Since the launch of its LIZHI App in 2013, LIZHI has cultivated a vibrant and growing community encouraging audio content creation and sharing. Now LIZHI is an audio wonderland offering a wide range of podcasts and audio entertainment products and features, including audio live streaming and various interactive audio social products, empowering users to enjoy an immersive and diversified entertainment experience through audio.

LIZHI envisions a global audio community – a place where everyone can create, share and connect with each other through voices and across cultures.

For more information, please visit: http://ir.lizhi.fm.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the Securities Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

LIZHI INC.

IR Department

Tel: +86 (20) 3866-4265

E-mail: [email protected]

The Piacente Group, Inc.

Jenny Cai

Tel: +86 (10) 6508-0677

E-mail: [email protected]

In the United States:

The Piacente Group, Inc.

Brandi Piacente

Tel: +1-212-481-2050

E-mail: [email protected] 

LAS VEGAS, Jan. 13, 2021 (GLOBE NEWSWIRE) — Sightline Payments, leader in cashless gaming and betting solutions, today announced it has partnered with Boyd Gaming and Aristocrat Technologies to serve as the patron’s funding solution for the new cashless gaming offering at its Blue Chip Casino in Michigan City, Indiana.

The new jointly developed experience represents a true, end-to-end digital cashless ecosystem. Patrons of Blue Chip Casino will be able to load funds electronically from a personal account of their choice, after which they can then safely and securely use the digital cash to make wagers directly on their favorite slot machines. When done, any funds left on the slot machine can be optionally transferred back to their Digital Wallet to be used at another game in the casino. In future phases the solution will be expanded to include table games, restaurants, and a host of other amenities at Blue Chip.

“Building on our partnership with Sightline and Aristocrat, we are proud to introduce a solution that has been designed from the ground-up to give our guests an unmatched cashless experience offering convenience, safety, and security,” said Blake Rampmaier, Senior Vice President and Chief Information Officer of Boyd Gaming.

Recently, the American Gaming Association (AGA) conducted research that shows consumers desire for digital payment options given pandemic-related health concerns:

• 59 percent of past-year casino visitors are less likely to use cash in their everyday lives because of the COVID-19 pandemic
• 57 percent of past-year casino visitors report the option for digital or contactless payments on the casino floor is important to them because of the COVID-19 pandemic

Through the partnership between Boyd Gaming, Aristocrat Technologies and Sightline Payments, Blue Chip Casino can now offer an integrated state-of-the-art cashless digital payment solution with robust customer loyalty.

“Sightline thanks Boyd Gaming for its vision and congratulates Blue Chip and Aristocrat on this launch,” said Joe Pappano, Chief Executive Officer of Sightline. “A mobile-centric payments ecosystem that works across all channels and verticals is the future of all regulated gaming in the United States.”

Over the coming months, pending regulatory approvals, Boyd intends to expand these capabilities to its patrons nationwide and extend the utility of the ecosystem to all patron-facing touchpoints.       

“At Aristocrat we believe in creating exceptional customer experiences and we are deeply grateful to Boyd in entrusting us to create such an experience for their patrons. This collaboration between Boyd Gaming, Sightline Payments and Aristocrat Technology will serve as a blueprint for the path forward for the industry,” said Cath Burns, Executive Vice President of Customer Experience Solutions for Aristocrat.

About Sightline Payments

Sightline was founded in 2010 and awarded Deloitte’s prestigious Technology Fast 500TM in 2019. The company is leading the way in gaming to build the first truly cashless ecosystem with its flagship solution, Play+. Named “Most Innovative Gaming Technology Product of the Year”, Play+ allows consumers a cashless and seamless mobile commerce experience for hospitality and gaming, including online, mobile, on-premise slots, table games, and sports. The Play+ digital platform is embraced by integrated casino resorts, sports betting and lottery platforms, including the largest and most well-recognized casino resort and sports betting brands in the world. Sightline is based in Las Vegas, Nevada.  Learn more at https://sightlinepayments.com/.

Media Contacts:

Sightline Payments

Susan Donahue
Skyya PR for Sightline Payments
Ph: (646) 454-9378
E: [email protected]

MADISON, Wis., Jan. 13, 2021 (GLOBE NEWSWIRE) — Sonic Foundry, the trusted global leader for video creation and management solutions as well as virtual and hybrid events, today announced the appointment of two new senior vice presidents. These new positions support the company’s efforts to create new revenue streams, open new market share, and increase customer satisfaction and report directly to CEO Joe Mozden Jr.  

Steve McKee is SVP Product & Technology where he leads the company’s product development efforts, ensuring the Mediasite solutions brought to the current and new markets continue to meet industry demands. McKee brings over 30 years of experience in product and operations leadership for fast-growing technology organizations.  His most recent role was Head of Product at Gloo, a SaaS company that uses technology to accelerate the growth of the digital church and transform personal growth in churches and other social service organizations. Prior, he served as SVP of Marketing Platforms at Wiland, a marketing intelligence firm and VP, Marketing Technology Group at Merkle, Inc., a global customer experience management company.  

Duane Glader is SVP Sales & Marketing, leading the company’s North American sales and global marketing efforts. He comes from DeVry University where he served as Senior Director Strategic Accounts for the past four years. A business growth senior sales leader, Glader has a track record in Fortune 1000 B2B sales, key account management and emerging markets. Prior, he served as Director of Business Development at Colorado Technical University where he led the national sales team.  

“These new positions on our team reflect our company’s commitment to creating new growth, and I am excited to welcome Steve and Duane to Sonic Foundry. They both have highly entrepreneurial backgrounds with impressive track records of driving new product and sales growth,” said Joe Mozden Jr., CEO, Sonic Foundry. “I am confident that they – alongside our extremely dedicated employees who continue to make Mediasite the trusted partner for schools and organizations worldwide – will help to expand our current video footprint and offer new ideas for how we will evolve our solutions during this unprecedented time in the enterprise video industry’s history.”  

About Sonic Foundry®, Inc.

Sonic Foundry (OTC: SOFO) is the global leader for video capture, management and streaming solutions, as well as virtual and hybrid events. Trusted by more than 5,200 educational institutions, corporations, health organizations and government entities in over 65 countries, its Mediasite Video Platform quickly and cost-effectively automates the capture, management, delivery and search of live and on-demand streaming videos. Learn more at www.mediasite.com and @mediasite.

© 2021 Sonic Foundry, Inc. Product and service names mentioned herein are the trademarks of Sonic Foundry, Inc. or their respective owners.

Media Contact: Nicole Wise, Director of Communications
Sonic Foundry
920.226.0269
[email protected]

San Clemente, CA, Jan. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global WholeHealth Partners Corp, a multinational supplier of over 70+ with 56 products FDA approved and several approved for export only including Dengue, Ebola, Zika, Malaria and also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the pandemic out of control in the United States, the nation’s coronavirus testing system is starting to strain again.

Global WholeHealth Partners, Corp (OTC:GWHP) Announces New Purchase Agreement From RyZac Health as Order Size Increases of over 3 times larger from Initial Order, verified by letter from Michael Dwyer, the president of RyZac Health.

While discussing Covid-19 Antibody rapid tests and the market with Charles Strongo, CEO of Global WholeHealth Partners, Corp, RyZac Health CEO, Michael Dwyer said in his letter “your amazing 99.4% accuracy is outperforming most in the market.” 

The market is growing because of the outbreak of the coronavirus (SARS CoV-2) pandemic, which has increased the demand for rapid testing across the world. As the number of people suffering from the viral infection increases, the demand for rapid testing, which allows detecting the virus quickly, is growing. The adoption of a population-wide testing approach, which includes household, individual testing, is one of the trends influencing the demand for Covid-19 diagnostics kits. The shift from symptomatic testing to mass testing in developed countries is another major factor affecting the market.

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.

With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.

As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.

About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more — 193 million a month, according to one report — to be effective.

The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test.

Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.

GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Media Contact:

Name: Charles Strongo,

CEO, Global WholeHealth Partners Corp.

Email: [email protected]

www.gwhpcorp.com

https://www.globenewswire.com/news-release/2020/12/11/2143930/0/en/The-global-COVID-19-diagnostics-market-by-revenue-is-expected-to-register-a-negative-CAGR-of-9-during-the-period-2021-2026.html

Forward-Looking Statements

This press release contains “forward-looking statements.”  Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

FORT LAUDERDALE, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) — LMP Automotive Holdings, Inc. (NASDAQ: LMPX) (the “Company” or “LMP”), an e-commerce and facilities-based platform for consumers who desire to buy, sell, subscribe to or finance pre-owned and new automobiles, today announced it has revised its agreements to acquire Atlantic Automotive Group (“AAG”) to a combination of cash and LMPX common stock and to exclude certain dealerships owned by AAG in a deal valued at $330 million.

• Acquisition agreements include revised transaction terms from the transaction previously announced on October 9, 2020

• Includes Atlantic Central Storage, eight dealership locations consisting of nine import and domestic franchise brands along with several management companies that generated approximately $655 million revenue and $25.1 million in net income in calendar year 2020

• Real estate leased with an option to purchase owned properties

• LMP’s 70% partnership interest purchase is comprised of $40 million in LMPX common stock with a floor of $57 per share and $191 million in cash

• Acquisition is inclusive of approximately $34.7 million of working capital and FF&E and is expected to be immediately accretive to cash flow and earnings upon close, adding $15 million in annualized net income or $1.35 per share in 2021 and 16.9 million in net income or $1.52 per share in full year 2022 based on an estimated 11.1 million shares to be outstanding after closing. We expect to close the transaction in April of this year

• Adds approximately 610 employees to LMP’s partnership portfolio companies

• Atlantic Automotive Group’s ownership and management will continue to operate the business post-closing

• Upon closing and combined with our previously contracted stage 1 acquisitions which are expected to close this month, LMP’s revenues are expected to exceed $1.3 billion, with approximately $36 million in net income or $3.24 per share in 2021 on an annualized basis and $1.4 billion, with approximately $39 million in net income or $3.51 per share in 2022 inclusive of synergies and adds over 1,100 employees in our partnership portfolio companies

Sam Tawfik, LMP’s Chief Executive Officer stated, “On behalf of myself, LMP and our Board of Directors, I want to welcome and thank the Atlantic team on our prospective partnership. Atlantic has been recognized in the past as a top 8 dealership group in the U.S. as measured by revenue and is a leader in automotive retail. We are all looking forward to working together and expanding upon Atlantic’s previous success. We expect to close our previously-announced stage 1 acquisitions this month, and the Atlantic acquisition by April, subject to customary closing conditions and manufacturer approval.”

Richard Aldahan, LMP’s Chief Operating Officer added, “This restructured partnership combined with our stage 1 deals in contract brings our total contracted new vehicle franchise count to 21, operating at 15 locations, and our pre-owned dealership count to 5 locations with vehicle unit sales of roughly 39,500 in 2020 with a 52% new to used mix along with additional vehicle storage capacity of over 5,000 vehicles between the Northeast and Southeastern United States. This is an important addition to our network given Atlantic’s dominant and clustered presence in New York, one of the most lucrative markets in the United States. Atlantic’s vehicle fulfillment, reconditioning and service capacity will cost-effectively expand our free delivery radius and cut out multiple legs of costly transportation, logistics and reconditioning costs. We look forward to working with our future teammates at Atlantic,” Mr. Aldahan concluded.

Evan Bernstein, LMP’s Chief Financial Officer commented, ” The Atlantic partnership is expected to add an estimated $655 million in revenue, $15 million in net income on an annualized basis in 2021 or $1.35 per share and 16.9 million in net income or $1.52 per share in full year 2022 inclusive of synergies and based on an estimated 11.1 million shares to be outstanding after closing. Under our previously signed agreement with a purchase price of $397.6 million for LMP’s 70% partnership interest which we terminated, we had expected to be accretive to earnings in an amount equal to $3.18 per share and net income of $38 million on an annualized basis. With Atlantic’s newly structured deal, combined with our currently contracted acquisitions which we expect to close this month, we anticipate combined expected revenues to exceed $1.3 billion, with approximately $36 million in net income or $3.24 per share in 2021 on an annualized basis and $1.4 billion, with approximately $39 million in net income or $3.51 per share in 2022 inclusive of synergies.” Mr. Bernstein added, “We are seeing a robust acquisition market as we continue to build our pipeline of prospective dealership partnerships and intend on accelerating our acquisition strategy moving forward in our targeted regions, as well as recruiting additional management and promoting within our portfolio companies.” Mr. Bernstein concluded.

CONFERENCE CALL

Management will host an investor conference call at 10:00 a.m. ET on Wednesday, January 13, 2021 to discuss the Company’s recently announced acquisition and conclude with Q&A from participants.

All interested parties can join the call by dialing (877) 407-3982 or (201) 493-6780. A webcast of the call may be accessed at: http://public.viavid.com/index.php?id=143027.

An archived webcast of the conference call will be accessible from the Investor Relations section of the company’s website, https://investors.lmpah.com/.

A telephonic replay of the conference call will be available through Wednesday, January 27, 2021 by dialing (844) 512-2921 or (412) 317-6671 and entering passcode 13715029.

ABOUT LMP AUTOMOTIVE HOLDINGS, INC. – “BUY, SUBSCRIBE, SELL AND REPEAT.”

LMP Automotive Holdings, Inc. (NASDAQ: LMPX) describes its business model as “Buy, Subscribe, Sell and Repeat.” This means that we “Buy” pre-owned automobiles primarily through auctions or directly from other automobile dealers, and new automobiles from manufacturers and manufacturer distributors. We “Subscribe” the automobiles to our customers by allowing them to enter into our subscription plan for automobiles in which customers have use of an automobile for a minimum of thirty (30) days. LMP’s vehicle subscription membership includes monthly swaps and offers the flexibility to return the vehicle without penalty, upgrade your vehicle to a more premium model or downgrade for a lesser cost model when you like. We “Sell” our inventory, including automobiles previously included in our subscription programs, to customers as well, and then we “Repeat” the whole process.

Investor Relations:

LMP Automotive Holdings, Inc.
500 East Broward Boulevard, Suite 1900
Fort Lauderdale, FL 33394
[email protected]

For more information visit: https://lmpmotors.com/.

FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” will,” the negatives thereof and other words and terms of similar meanings. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: our dependence upon external sources for the financing of our operations; our ability to effectively executive our business plan; our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our services and platform; our ability to manage the growth of our operations over time; our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others; our ability to maintain relationships with existing customers and automobile suppliers, and develop relationships; and our ability to compete and succeed in a highly competitive and evolving industry; as well as other risks described in our SEC filings. There is no assurance that any forward-looking statements will materialize. You are cautioned not to place undue reliance on forward-looking statements, which reflect expectations only as of this date. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

SOURCE: LMP Automotive Holdings, Inc.

VANCOUVER, British Columbia, Jan. 13, 2021 (GLOBE NEWSWIRE) — Corvus Gold Inc. (“Corvus” or the “Company”) – (TSX: KOR, NASDAQ: KOR) announces it has received initial core hole results from its new Lynnda Strip discovery east and west of the previously announced reverse circulation (RC) drill results (Figure 1) approximately 2km’s north of the Mother Lode deposit. The new results include hole ML20-167CT with 111.05m @ 0.80 g/t gold & hole ML20-169CT with an upper zone intercept of 52.64m @ 1.39 g/t gold and a lower zone intercept of 80.07m @ 0.83 g/t gold. These results continue to display consistent, oxide, high-grade vein mineralization and broad zones of heap leach grade mineralization which supports a large target potential at Lynnda Strip.

In addition, Corvus has received results from its initial hole (RC) drilled into the South Merlin target about a half a kilometre to the west of the initial Lynnda Strip discovery with a 12.2m intercept of 0.61 g/t gold before the hole ended due to poor drilling conditions. This far western intercept is believed to be connected to the overall Lynnda Strip system which would make it over 800 metres wide. Given the broad width of the system and Coeur Mining Inc’s recently announced results to the south, Corvus believes the greater Lynnda Strip system has strong potential (Figure 2) for further growth.

Jeffrey Pontius, President and CEO of Corvus, said, “These new results from the initial Lynnda Strip core holes have now extended oxide gold mineralization to a depth of 600 metres or an overall thickness of over 300 metres. We are encouraged by the South Merlin results and the thickness potential defined by these recent deep core holes. The good heap leach recoveries of the mineralization and the scale of the system suggests good open pit potential as well. Corvus will continue the aggressive expansion of the Lynnda Strip system as well as test a number of new and highly attractive targets in the area. It is a very exciting time for Corvus and its shareholders as district wide exploration continues to expand and interest level increases.”  

Executive Chairman Appointed

Corvus is pleased to announce that Ron Largent, the Company’s Chairman of the Board has accepted the new role as Executive Chairman and will take a greater role in the development of the Company’s assets.  Mr. Largent’s experience with mine development and operations gives Corvus an excellent, hands-on addition to its mine building team. 

Jeffrey Pontius, President and CEO of Corvus, said, “Ron’s new role as Executive Chairman is a positive for our Company.  Ron’s wealth of knowledge on mine construction and operations will significantly de-risk the development of our mining projects.  The solid working relationship I have had with Ron over the past few decades from our work on the development of the Cripple Creek mine in Colorado, to the Jerritt Canyon operation in Nevada, has built a high-level of confidence in his ability to build, optimize and operate mines.   Corvus and its shareholders are fortunate to have Ron in this strategic role as we advance the Company’s Nevada gold assets.” 

Ron Largent, Executive Chairman of Corvus, said, “Corvus has two excellent mining projects in Nevada, a premier jurisdiction for gold mining.  I feel fortunate to be part of the Corvus story and very excited about helping to advance the Company forward to the next stage of value creation.  Mining is always a challenging business but the unique assets of Corvus are well suited for low-cost development and are expected to operate across the full spectrum of the commodity price curve.”

Table 1: Lynnda Strip & South Merlin – New Discovery Drilling Results


(Reported intercepts are not true widths as there is currently insufficient data to calculate true orientation in space. Mineralized intervals are calculated using a 0.1 g/t cut-off unless otherwise indicated below)


Drill Hole #	from (m)	to (m)	Interval (m)	Gold (g/t)	Silver (g/t)	Comment
ML20-167CT	190.5	239.26	48.76	0.52	n/a	Upper Zone
AZ 090 dip-60
inc	201.59	205.25	3.66	1.97	n/a	1 g/t cut
	258.82	369.87	111.1	0.8	n/a
inc	293.12	303.7	10.58	1.08	n/a	Upper Vein #1
						1 g/t cut
inc	343.15	369.26	26.11	1.27	n/a	Upper Vein #1
						1 g/t cut
	395.33	419.44	24.11	0.81	n/a	Lower Zone
inc	402.95	407.52	4.57	1.24	n/a	Lower Vein #1
						1g/t cut
	422.76	432.91	10.15	0.5	n/a
	445.92	450.41	4.49	0.63	n/a
	455.07	463.91	8.84	0.37	n/a
	471.53	485.24	13.71	0.44	n/a
	490.97	516.64	25.67	0.26	n/a
	571.88	575.16	3.28	0.26	n/a
	580.64	585.06	4.42	0.37	n/a	Hole ended in oxide gold (0.67 g/t)
ML20-169CT	207.96	260.6	52.64	1.39	n/a	Upper Zone
AZ 090 dip-60
inc	209.26	238.8	29.54	2.15	n/a	Vein #1
						1 g/t cut
	309.98	325.22	15.24	0.32	n/a
	355.7	358.75	3.05	0.14	n/a
	391.03	471.1	80.07	0.83	n/a
inc	433.43	461.62	28.19	1.47	n/a	Lower Vein #1
						1 g/t cut
	490.69	524.87	34.18	0.36	n/a
	534.36	537.87	3.51	0.27	n/a
	541.63	561.81	20.18	0.25	n/a
	580.67	585.64	4.97	0.23	n/a
	672.1	682.81	10.71	0.12	n/a
ML20-172	99.06	112.78	13.72	0.13	n/a	South Merlin
AZ 085 dip-60						Upper Zone
	124.97	137.16	12.19	0.14	n/a
	160.02	188.98	28.96	0.2	n/a
	233.17	245.36	12.19	0.61	n/a	Lower Zone

https://www.globenewswire.com/NewsRoom/AttachmentNg/7436f0b6-c644-4912-8708-706c6a8c583f

Figure 1. Location map for new Lynnda Strip drill holes, East Bullfrog District, Nevada, ~2km North of the Mother Lode deposit 

https://www.globenewswire.com/NewsRoom/AttachmentNg/9634dc2f-027f-4455-87c4-9916c402f683

Figure 2. Aerial photo looking east at the new Lynnda Strip Discovery showing Corvus drilling and surrounding AngloGold Ashanti & Coeur Mining drilling

Qualified Person and Quality Control/Quality Assurance

Jeffrey A. Pontius (CPG 11044), a qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”), has supervised the preparation of the scientific and technical information that forms the basis for this news release and has reviewed and approved the disclosure herein. Mr. Pontius is not independent of Corvus, as he is the CEO & President and holds common shares and incentive stock options.

Carl E. Brechtel, (Nevada PE 008744 and Registered Member 353000 of SME), a qualified person as defined by NI 43-101, has coordinated execution of the work outlined in this news release and has also reviewed and approved the disclosure herein. Mr. Brechtel is not independent of Corvus, as he is the COO and holds common shares and incentive stock options.

The work program at Mother Lode was designed and supervised by Mark Reischman, Corvus Gold’s Nevada Exploration Manager, who is responsible for all aspects of the work, including the quality control/quality assurance program. On-site personnel at the project log and track all samples prior to sealing and shipping. Quality control is monitored by the insertion of blind certified standard reference materials and blanks into each sample shipment. All mineral resource sample shipments are sealed and shipped to American Assay Laboratories (“AAL”) in Reno, Nevada, for preparation and assaying. AAL is independent of the Company. AAL’s quality system complies with the requirements for the International Standards ISO 9001:2000 and ISO 17025:1999. Analytical accuracy and precision are monitored by the analysis of reagent blanks, reference material and replicate samples. Finally, representative blind duplicate samples are forwarded to AAL and an ISO compliant third-party laboratory for additional quality control. Mr. Pontius, a qualified person, has verified the data underlying the information disclosed herein, including sampling, analytical and test data underlying the information by reviewing the reports of AAL, methodologies, results and all procedures undertaken for quality assurance and quality control in a manner consistent with industry practice, and all matters were consistent and accurate according to his professional judgement. There were no limitations on the verification process.

Mr. Wilson, a qualified person, has verified the data underlying the information disclosed herein, including sampling, analytical and test data underlying the information by reviewing the reports of AAL, methodologies, results and all procedures undertaken for quality assurance and quality control in a manner consistent with industry practice, and all matters were consistent and accurate according to his professional judgement.  There were no limitations on the verification process.

Metallurgical testing on North Bullfrog and Mother Lode samples has been performed by McClelland Analytical Services Laboratories Inc. of Sparks Nevada (“McClelland”), Resource Development Inc. of Wheatridge, CO (RDi) and Hazen Research Inc. of Golden, CO (HRi). McClelland is an ISO 17025 accredited facility that supplies quantitative chemical analysis in support of metallurgical, exploration and environmental testing using classic methods and modern analytical instrumentation. McClelland has met the requirements of the IAS Accreditations Criteria for Testing Laboratories (AC89), has demonstrated compliance with ANS/ISO/IEC Standard 17025:2005, General requirements for the competence of testing and calibration laboratories, and has been accredited, since November 12, 2012. Hazen Research Inc. (“Hazen”), an independent laboratory, has performed flotation, AAO testing and cyanide leach testing on samples of sulphide mineralization from the YellowJacket zone and Swale area of Sierra Blanca, and roasting tests on Mother Lode flotation concentrate. Hazen holds analytical certificates from state regulatory agencies and the US Environmental Protection Agency (the “EPA”). Hazen participates in performance evaluation studies to demonstrate competence and maintains a large stock of standard reference materials from the National Institute of Standards and Technology (NIST), the Canadian Centre for Mineral and Energy Technology (CANMET), the EPA and other sources. Hazen’s QA program has been developed for conformance to the applicable requirements and standards referenced in 10 CFR 830.120 subpart A quality assurance requirements, January 1, 2002. Resource Development Inc. is a state-of-the-art laboratory for metallic and industrial minerals filling a need for high quality, cost-effective, and timely technical services for the international mining industry.

For additional information see the following: “Technical Report and Preliminary Economic Assessment for Gravity Milling and Heap Leach Processing at the North Bullfrog Project, Bullfrog Mining District, Nye County, Nevada”, dated November 21, 2020 with an effective date of October 7, 2020 and “Technical Report and Preliminary Economic Assessment for BIOX Mill and Heap Leach Processing at the Mother Lode Project, Bullfrog Mining District, Nye County, Nevada” dated November 21, 2020 with an effective date of October 7, 2020, each of which is available under Corvus’ profile on SEDAR at www.sedar.com.

About the North Bullfrog & Mother Lode Projects, Nevada

Corvus controls 100% of its North Bullfrog Project, which covers approximately 90.5 km² in southern Nevada.  The property package is made up of a number of private mineral leases of patented federal mining claims and 1,134 federal unpatented mining claims.  The project has excellent infrastructure, being adjacent to a major highway and power corridor as well as a large water right. The Company also controls 445 federal unpatented mining claims on the Mother Lode project which totals approximately 36.5 km² which it owns 100%.  The total Corvus 100% land ownership now covers over 127 km², hosting two major new Nevada gold discoveries.

About Corvus Gold Inc.

Corvus Gold Inc. is a North American gold exploration and development company, focused on its near-term gold-silver mining project at the North Bullfrog and Mother Lode Districts in Nevada. In addition, the Company controls a number of royalties on other North American exploration properties representing a spectrum of gold, silver and copper projects. Corvus is committed to building shareholder value through new discoveries and the expansion of its projects to maximize share price leverage in an advancing gold and silver market.

On behalf of
Corvus Gold Inc.

(signed) Jeffrey A. Pontius
Jeffrey A. Pontius,
President & Chief Executive Officer

Contact Information:	Ryan Ko
	Investor Relations
	Email: [email protected]
	Phone: 1-844-638-3246 (toll free) or (604) 638-3246

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and US securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements regarding the possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; potential expansion of the deposit; the rapid and effective capture of the potential of our Mother Lode project; the potential for new deposits and expected increases in the system’s potential; anticipated content, commencement and cost of exploration programs; anticipated exploration program results and expansion of existing programs; the discovery and delineation of mineral deposits/resources/reserves; the potential to discover additional high grade veins or additional deposits; the growth potential of the Mother Lode projects; and the potential for any mining or production at the Mother Lode projects, are forward-looking statements. Information concerning mineral resource estimates may be deemed to be forward-looking statements in that it reflects a prediction of the mineralization that would be encountered if a mineral deposit were developed and mined. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, variations in the nature, quality and quantity of any mineral deposits that may be located,
variations in the market price of any mineral products the Company may produce or plan to produce, the Company’s inability to obtain any necessary permits, consents or authorizations required for its activities, the Company’s inability to produce minerals from its properties successfully or profitably, to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies, and other risks and uncertainties disclosed in the Company’s 2020 Annual Information Form and latest interim Management Discussion and Analysis filed with certain securities commissions in Canada and the Company’s most recent filings with the United States Securities and Exchange Commission (the “SEC”). The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. All of the Company’s Canadian public disclosure filings in Canada may be accessed via

www.sedar.com

and filings with the SEC may be accessed via

www.sec.gov

and readers are urged to review these materials, including the technical reports filed with respect to the Company’s mineral properties.

Cautionary Note to US Investors

NI 43-101 is a rule developed by the Canadian Securities Administrators which establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. Unless otherwise indicated, all resource estimates contained in or incorporated by reference in this press release have been prepared in accordance with NI 43-101 and the guidelines set out in the Canadian Institute of Mining, Metallurgy and Petroleum (the “CIM”) Standards on Mineral Resource and Mineral Reserves, adopted by the CIM Council on November 14, 2004 (the “CIM Standards”) as they may be amended from time to time by the CIM.

United States investors are cautioned that the requirements and terminology of NI 43-101 and the CIM Standards differ significantly from the requirements and terminology of the SEC set forth in the SEC’s Industry Guide 7 (“SEC Industry Guide 7”). Accordingly, the Company’s disclosures regarding mineralization may not be comparable to similar information disclosed by companies subject to SEC Industry Guide 7. Without limiting the foregoing, while the terms “mineral resources”, “inferred mineral resources”, “indicated mineral resources” and “measured mineral resources” are recognized and required by NI 43-101 and the CIM Standards, they are not recognized by the SEC and are not permitted to be used in documents filed with the SEC by companies subject to SEC Industry Guide 7. Mineral resources which are not mineral reserves do not have demonstrated economic viability, and US investors are cautioned not to assume that all or any part of a mineral resource will ever be converted into reserves. Further, inferred resources have a great amount of uncertainty as to their existence and as to whether they can be mined legally or economically. It cannot be assumed that all or any part of the inferred resources will ever be upgraded to a higher resource category. Under Canadian rules, estimates of inferred mineral resources may not form the basis of a feasibility study or prefeasibility study, except in rare cases. The SEC normally only permits issuers to report mineralization that does not constitute SEC Industry Guide 7 compliant “reserves” as in-place tonnage and grade without reference to unit amounts. The term “contained ounces” is not permitted under the rules of SEC Industry Guide 7. In addition, the NI 43-101 and CIM Standards definition of a “reserve” differs from the definition in SEC Industry Guide 7. In SEC Industry Guide 7, a mineral reserve is defined as a part of a mineral deposit which could be economically and legally extracted or produced at the time the mineral reserve determination is made, and a “final” or “bankable” feasibility study is required to report reserves, the three-year historical price is used in any reserve or cash flow analysis of designated reserves and the primary environmental analysis or report must be filed with the appropriate governmental authority. The mine economics presented herein and derived from the PEA are preliminary in nature and may not be realized. The PEA is not a feasibility study. U.S. investors are urged to consider closely the disclosure in our latest reports and registration statements filed with the SEC. You can review and obtain copies of these filings at http://www.sec.gov/edgar.shtml. U.S. Investors are cautioned not to assume that any defined resource will ever be converted into SEC Industry Guide 7 compliant reserves.

This press release is not, and is not to be construed in any way as, an offer to buy or sell securities in the United States.

The United States Securities and Exchange Commission (“SEC”) limits disclosure for U.S. reporting purposes to mineral deposits that a company can economically and legally extract or produce. Resource estimates contained in this press release are made pursuant to NI 43-101 standards in Canada and do not represent reserves under the standards of the SEC’s Industry Guide 7. Under the currently applicable SEC Industry Guide 7 standards, a “final” or “bankable” feasibility study is required to report reserves, the three-year historical average price is used in any reserve or cash flow analysis to designate reserves and all necessary permits and government approvals must be filed with the appropriate governmental authority. This press release uses the terms “Measured Resources”, “Indicated Resources”, and “Inferred Resources”. We advise U.S. investors that while these terms are Canadian mining terms as defined in accordance with NI 43-101, such terms are not recognized under SEC Industry Guide 7 and normally are not permitted to be used in reports and registration statements filed with the SEC. Mineral resources described in this press release have a great amount of uncertainty as to their economic and legal feasibility. The SEC normally only permits issuers to report mineralization that does not constitute SEC Industry Guide 7 compliant “reserves” as in-place tonnage and grade, without reference to unit measures. “Inferred Resources” have a great amount of uncertainty as to their existence, and great uncertainty as to their economic and legal feasibility. It cannot be assumed that any or all part of an Inferred Resource will ever be upgraded to a higher category.

U.S. Investors are cautioned not to assume that any part or all of mineral deposits in these categories will ever be converted into SEC Industry Guide 7 reserves.

• The Three Products Are Expected to Be Launched, Subject to Israeli Ministry of Health Approval, Between 2022 and 2024
• Potential Collective Maximum Sales of the Three Products in the Israeli Market is Estimated at $5-$7 Million Annually
• These Sales Are i
  n Addition to the Potential $20-$30 Million from the Recently Licensed Alvotech Biosimilar Portfolio
  

REHOVOT, Israel, Jan. 13, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that the Company has entered into agreements with two undisclosed international pharmaceutical companies to commercialize three biosimilar product candidates in Israel. Subject to approval by the European Medicines Agency (EMA) and subsequently by the Israeli Ministry of Health (IMOH), the three products are expected to be launched in Israel between 2022 and 2024. The two pharmaceutical companies will maintain development, manufacturing, and supply responsibilities for these three products.

“These agreements expand our pipeline of biosimilar product candidates for distribution in Israel, which already includes six products previously licensed from Alvotech, and further position Kamada as a leader in the emerging biosimilar market in Israel,” said Amir London, CEO of Kamada. “The Israeli market for the referenced innovative products to which these three biosimilar products are targeted was between approximately $20-$25 million in 2019, and we estimate the potential collective maximum sales generated by the distribution of these three products, achievable following regulatory approval and within several years of launch, to be in the range of $5-$7 million annually. These sales will be in addition to the $20-$30 million of potential maximum sales of the six Alvotech biosimilar products, which, subject to approval by the EMA and subsequently by the IMOH, are expected to be launched between 2022 and 2025. The distribution of this biosimilar portfolio is expected to further support the anticipated future revenue and profitability growth in our Distribution Products segment.”

About Kamada

Kamada Ltd. (“the Company”) is a commercial stage plasma-derived biopharmaceutical company focused on orphan indications, with an existing marketed product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived immune globulins. The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other countries through local distributors. Pursuant to an agreement with Takeda the Company will continue to produce Glassia for Takeda through 2021 and Takeda is planning to initiate its own production of Glassia for the U.S. market in 2021 at which point Takeda will commence payment of royalties to the Company. The Company’s second leading product is KamRab®, a rabies immune globulin (Human) for post-exposure prophylaxis against rabies infection. KamRab is FDA approved and is being marketed in the U.S. under the brand name KEDRAB® through a strategic partnership with Kedrion S.p.A. In addition to Glassia and KEDRAB, the Company has a product line of four other plasma-derived pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. The Company has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, the Company’s intravenous AAT is in development for other indications, such as GvHD and prevention of lung transplant rejection, and during 2020, the Company initiated the development of a plasma derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). The Company leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) approval by EMA and subsequently by IMOH of the three new biosimilar products; 2) Israeli launch of the three new biosimilar products between 2022 through 2024; 3) Kamada’s position as a leader in the emerging biosimilar market in Israel; 4) Kamada’s estimation that the potential maximum sales generated from the distribution of the three products, achievable after regulatory approval and within several years of launch, to be in the range of $5-$7 million annually; 5) approval by EMA and subsequently by IMOH of the six biosimilar products licensed from Alvotech; 6) Kamada’s expectation to launch six biosimilar products licensed from Alvotech during 2022-2025; 7) Kamada’s estimation that the potential maximum sales generated by the distribution of the six biosimilar products licensed from Alvotech, after regulatory approval and achievable within several years of launch, to be in the range of $20-$30 million annually; and 8) expectations that Kamada’s Distribution segment will continue to grow in revenues and profitability in the coming years. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, delays in the approval by the EMA and IMOH of the biosimilar products, additional competition in the biosimilar market in which Kamada operates, prevailing market conditions, corporate events associated with our partners, including the two undisclosed entities, and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:

Chaime Orlev
Chief Financial Officer
[email protected]

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

WINDSOR, Conn., Jan. 13, 2021 (GLOBE NEWSWIRE) — Scapa Healthcare, the trusted strategic partner of choice for the world’s leading companies in advanced wound care, consumer wellness and medical device & fixation, today announced expanded medical-grade adhesive coating capabilities in its Windsor, CT and Gargrave, UK facilities. The newly added coating lines increase Scapa’s capacity to custom design and produce polyurethane and polyvinyl chloride foams coated with silicone gels, water-based and solvent-based acrylic adhesives. Scapa has the additional capability of lamination and adhesive coating of non-wovens, breathable films, unsupported adhesives and many other substrates. This expansion strengthens the company’s ability to offer solid vertical integration with other Scapa sites to provide better economies of scale to medical device manufacturers.

The expanded medical adhesive coating capacity further enhances Scapa Healthcare’s leading position in offering complete contract development and manufacturing capabilities, from coating to conversion to packaging and sterilisation of finished products. Furthermore, Scapa features unparalleled design expertise in the creation of innovative medical-grade adhesive solutions for medical device manufacturers. This includes the company’s own Soft-Pro® adhesive range that meets needs spanning from high tack to low trauma and short-term to long-term wear requirements.

“Our team of dedicated experts and full range of turn-key capabilities enable Scapa Healthcare to rapidly take a product from concept to market faster than many of our partners can do internally,” said John Petreanu, president of Scapa Healthcare. “The increased medical-grade adhesive coating capability further strengthens our value proposition and enables us to offer innovative and customized turn-key solutions to customers worldwide.”

With development and manufacturing facilities throughout North America and Europe, Scapa offers single-source, dual supply to its partners. Scapa Healthcare’s facilities are ISO-certified and FDA registered with Cleanrooms and environmentally controlled rooms for full-scale production of finished goods.

Learn more about Scapa’s extensive medical-grade adhesive coating capabilities here.

About Scapa Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world’s leading companies in advanced wound care, consumer wellness and medical device & fixation. Our strategy is to partner with market leaders to develop and manufacture innovative skin friendly medical device fixation and topical solutions. Through pursuing these partnerships, Scapa now provides integrated services to the top global MedTech companies. Our state-of-the-art facilities enable Scapa Healthcare to offer customers the whole spectrum of production services from inception through to market delivery. For more information, visit: scapahealthcare.com or email [email protected]

Media Contact
Hillary Lima
SVM Public Relations and Marketing Communications
[email protected]
(401) 490-9700